This article is a correction to:
Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3
Yinteng Wu1†
Bo Zhang2†Juan Nong3†
Raquel Alarcon Rodriguez4Wenliang Guo5Ying Liu6
Shijian Zhao7*
Ruqiong Wei6*- 1Department of Orthopedic and Trauma Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- 2Department of Trauma Hand Surgery, The Second Nanning People’s Hospital, Nanning, Guangxi, China
- 3Department of Joint Surgery, The Second Nanning People’s Hospital, Nanning, Guangxi, China
- 4Faculty of Health Sciences, University of Almerìa, Almeria, Spain
- 5Department of Rehabilitation Medicine, Guigang City People’s Hospital, Guigang, China
- 6Department of Rehabilitation Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- 7Department of Cardiology, The Affiliated Cardiovascular Hospital of Kunming Medical University (Fuwai Yunnan Cardiovascular Hospital), Kunming, Yunnan, China
A Corrigendum on
Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3
by Wu Y, Zhang B, Nong J, Rodrìguez RA, Guo W, Liu Y, Zhao S and Wei R (2023). Front. Genet. 14:1045061. doi: 10.3389/fgene.2023.1045061
In the published article, there was an error in Figure 1D as published. The figure was misspelled during the rework process. The corrected Figure 1 and its caption are given below.
FIGURE 1
FIGURE 1. Expression of P4HA3 in normal and tumor tissues. (A) P4HA3 expression across 31 regular tissues and (B) 21 tumor cell lines. The mRNA expression landscape of P4HA3 in (C) tumor tissue on TCGA database and (D) expression of P4HA3 in normal and tumor tissues (*p < 0.05, **p < 0.01, and ***p < 0.001; ns: no significance). p values were based on the Wilcoxon rank sum test.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: prolyl 4-hydroxylase subunit alpha 3 (P4HA3), pan-cancer, the tumor microenvironment (TME), collagen, immunotherapy, epithelial-mesenchymal transition (EMT)
Citation: Wu Y, Zhang B, Nong J, Alarcon Rodriguez R, Guo W, Liu Y, Zhao S and Wei R (2023) Corrigendum: Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3. Front. Genet. 14:1204421. doi: 10.3389/fgene.2023.1204421
Received: 12 April 2023; Accepted: 12 May 2023;
Published: 23 May 2023.
Edited and reviewed by:
James Hicks, University of Southern California, United StatesCopyright © 2023 Wu, Zhang, Nong, Alarcon Rodriguez, Guo, Liu, Zhao and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ruqiong Wei, weiruqiongspain@163.com; Shijian Zhao, zhaoshijian1025@163.com
†These authors have contributed equally to this work and share first authorship